This study is accepting new patients by invitation only
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Summary
- Eligibility
- for people ages 18-85 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Cytokinetics
- ID
- NCT04848506
- Phase
- Phase 2/3 Cardiomyopathy Research Study
- Study Type
- Interventional
- Participants
- Expecting 900 study participants
- Last Updated